Selective Cox-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential

by John Vane (Editor), Jack H. Botting (Editor)

Overview

This volume is the proceedings of the William Harvey Research Conference held in Cannes, France, on the 20th and 21st March, 1997. It describes the present knowledge of the structures of the cyclooxygenase isoforms and the experimental and clinical effects of selective inhibitors of cyclooxygenase-2. The pathophysiological significance of the cyclooxygenase enzymes in tumorigenesis, programmed cell death, vascular disease and asthma is also covered.

Product Details

ISBN-13:	9780792387299
Publisher:	Springer-Verlag New York, LLC
Publication date:	01/28/1998
Pages:	150
Product dimensions:	6.14(w) x 9.21(h) x 0.44(d)

About the Author

Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK.
Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids.

Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK.